Omeprazole

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS

Retrieved on: 
화요일, 4월 30, 2024
Pain, FDA, Omeprazole, Fungal infection, Gastroenterology, Lactulose, PIN, Skin, Clarithromycin, Nausea, Hyponatremia, Infection, Paracetamol, Amoxicillin, Cardiomyopathy, Duchenne muscular dystrophy, Helicobacter pylori, Vomiting, Patient, Idiopathic pulmonary fibrosis, Constipation, Granisetron, Multimedia, Health, Acetylcysteine, Fever, Ibuprofen

NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.

Key Points: 
  • NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.
  • A conference call will be held on May 7 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on providing unique products that improve patient care.

RedHill Announces New USPTO Patent Covering Talicia® Through 2034

Retrieved on: 
월요일, 3월 11, 2024
QIDP, Rifabutin, Face, Patent, Patient, Amoxicillin, Regulatory affairs, Helicobacter pylori, Gastroenterology, Omeprazole, Senior, BMI, FDA, TEL, GAIN, Pharmaceutical industry

TEL AVIV, Israel and RALEIGH, N.C., March 11, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new U.S. patent covering Talicia1 as an all-in-one fixed-dose combination of amoxicillin, omeprazole and rifabutin and its use for the treatment of helicobacter pylori (H. pylori) infection (Patent No. 11,931,463 to be issued March 19, 20244). Talicia is the leading branded first-line therapy prescribed by U.S. gastroenterologists for H. pylori infection, which affects approximately 35% of the U.S. adult population and this patent is expected to provide protection for Talicia until February 12, 2034.

Key Points: 
  • 11,931,463 to be issued March 19, 20244).
  • Talicia is the leading branded first-line therapy prescribed by U.S. gastroenterologists for H. pylori infection, which affects approximately 35% of the U.S. adult population and this patent is expected to provide protection for Talicia until February 12, 2034.
  • "Talicia is the only FDA-approved rifabutin-containing all-in-one therapy for the eradication of H. pylori.
  • Its components and formulation are optimized to provide patients with the right medications for successful H. pylori eradication with an optimized resistance profile, which is significant in the face of growing microbial resistance to clarithromycin-based regimens," said Patricia Anderson, RedHill's Senior Vice President of Regulatory Affairs.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS

Retrieved on: 
화요일, 2월 27, 2024
Fever, Ibuprofen, Clarithromycin, PIN, Lactulose, Multimedia, FDA, Acetylcysteine, Pain, Omeprazole, Granisetron, Amoxicillin, Idiopathic pulmonary fibrosis, Skin, Nausea, Vomiting, Constipation, Duchenne muscular dystrophy, Cardiomyopathy, Fungal infection, Hyponatremia, Paracetamol, Health, Patient, Helicobacter pylori, Infection, Gastroenterology

NASHVILLE, Tenn., Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024.

Key Points: 
  • NASHVILLE, Tenn., Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024.
  • A conference call will be held on March 5 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.

SYNEVIT® Embraces Supplemental Synergy

Retrieved on: 
목요일, 11월 30, 2023
Pain, Paracetamol, Pharmacist, Health, Omeprazole, Research, Zinc, Element, RDA, Cvetkovski, Ibuprofen, Dietary supplement

FORT LAUDERDALE, Fla., Nov. 30, 2023 /PRNewswire/ -- The pharmaceutical world often focuses on specific ingredients. If an individual is in pain, they can take ibuprofen or acetaminophen. If they have digestive issues, they might take omeprazole. These highly targeted medical solutions have their place. However, the team at SYNEVIT® firmly believes that when an individual seeks natural, nutraceutical health and wellness support, they should think beyond single ingredients.

Key Points: 
  • However, the team at SYNEVIT® firmly believes that when an individual seeks natural, nutraceutical health and wellness support, they should think beyond single ingredients.
  • "Our motto is Technology in Synergy with Nature®," explains SYNEVIT® founder and CEO George Cvetkovski.
  • "Everything matters when creating nutraceutical formulas, including what ingredient you combine and the concentration of each one," Cvetkovski concludes.
  • We're always trying to upgrade our formulas to make sure all of the ingredients are working together to create synergistic results.

DASYNOC™ Uptake into the Blood Remains Consistent When Taken with Omeprazole, Whereas SPRYCEL® Uptake is Significantly More Impaired than Previously Understood

Retrieved on: 
수요일, 11월 8, 2023
Biotechnology, Pharmaceutical, Health, Oncology, PH, FDA, AUC, PPI, Omeprazole, Physician, CML, HIV disease progression rates, Dasatinib, Risk, TKI, Blood, Patient, Death, Solubility, Pharmaceutical industry, Cmax

Xspray has demonstrated that in the DASYNOC CO-PPI Study, DASYNOC’s uptake into blood was not affected 10 hours after taking omeprazole (107 % of intended AUC0-24h and 86% of intended Cmax).

Key Points: 
  • Xspray has demonstrated that in the DASYNOC CO-PPI Study, DASYNOC’s uptake into blood was not affected 10 hours after taking omeprazole (107 % of intended AUC0-24h and 86% of intended Cmax).
  • However, in the SPRYCEL CO-PPI Study, the uptake of SPRYCEL was significantly reduced 10 hours after taking omeprazole (only 12% of the intended AUC0-24h and 4% of the intended Cmax).
  • “We recently published that CML patients, concomitantly treated with TKIs and PPIs, are at a statistically significant 3.5-fold increased risk of death.
  • SPRYCEL was approved in 2006 by the FDA and is the market leading branded product that revolutionized the treatment of CML.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS

Retrieved on: 
화요일, 10월 31, 2023
Gastroenterology, Duchenne muscular dystrophy, Ibuprofen, FDA, Constipation, Clarithromycin, Granisetron, PIN, Hyponatremia, Lactulose, Vomiting, Omeprazole, Cardiomyopathy, Fungal infection, Skin, Infection, Health, Nausea, Multimedia, Helicobacter pylori, Fever, Acetylcysteine, Paracetamol, Pain, Patient, Amoxicillin, Idiopathic pulmonary fibrosis, Pharmaceutical industry, Vaccine, Online shopping

NASHVILLE, Tenn., Oct. 31, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the third quarter 2023 financial results and provide a company update after the market closes on Tuesday, Nov. 7, 2023.

Key Points: 
  • NASHVILLE, Tenn., Oct. 31, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the third quarter 2023 financial results and provide a company update after the market closes on Tuesday, Nov. 7, 2023.
  • A conference call will be held on Nov. 7 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on the delivery of high-quality, prescription brands designed to improve patient care.

i2o Therapeutics Names Kurt Graves Chairman and CEO, Announces Corporate Updates

Retrieved on: 
월요일, 8월 28, 2023
Health, Diabetes, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Executive, Obesity, Prevalence, Harvard University, The Conference Board, Intarcia Therapeutics, Disability, EVP, Policy, Intarsia, PYY, Ionic liquid, IP, Glucagon, Medication, Novartis, Acquisition, Omeprazole, Vertex Pharmaceuticals, ITCA, Merck, Commercial, Therapy, Lancet, Death, House of Medici, Society, GI, Peptide, Disease, Corporate development, Pharmaceutical industry

i2o Therapeutics, Inc. today announced the appointment of Kurt Graves as Chairman, President and CEO.

Key Points: 
  • i2o Therapeutics, Inc. today announced the appointment of Kurt Graves as Chairman, President and CEO.
  • Mr. Graves succeeds i2o co-founder and CEO Ravi Srinivasan, Ph.D., who is pursuing other leadership opportunities within the life sciences field.
  • He has previously served as Chairman, President and CEO of Intarcia Therapeutics, former Chairman of Radius Health, former Executive Chairman of i2o Therapeutics, and as a Board member at Achillion Pharmaceuticals until it was acquired, and at Seres Health.
  • Previously, Mr. Graves served as EVP, Head of Corporate Development, Strategic Drug Development and Program Management and Head of Commercial at Vertex Pharmaceuticals.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS

Retrieved on: 
화요일, 8월 1, 2023
Idiopathic pulmonary fibrosis, Lactulose, Gastroenterology, Fever, Acetylcysteine, Constipation, Hyponatremia, Multimedia, Duchenne muscular dystrophy, Pain, Vomiting, Helicobacter pylori, PIN, Patient, Paracetamol, Amoxicillin, Call Me, Omeprazole, Granisetron, Nausea, Fungal infection, Ibuprofen, Infection, Cardiomyopathy, FDA, Health, Clarithromycin, Skin, Pharmaceutical industry, Vaccine, Online shopping

NASHVILLE, Tenn., Aug. 1, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the second quarter 2023 financial results and provide a company update after the market closes on Tuesday, Aug. 8, 2023.

Key Points: 
  • NASHVILLE, Tenn., Aug. 1, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the second quarter 2023 financial results and provide a company update after the market closes on Tuesday, Aug. 8, 2023.
  • A conference call will be held on Aug. 8 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on the delivery of high-quality, prescription brands designed to improve patient care.

Phil and RedHill Biopharma Partner to Increase Access to Talicia®

Retrieved on: 
목요일, 7월 6, 2023
Software, Research, General Health, Networks, Pharmaceutical, Data Management, Technology, Infectious Diseases, Health Technology, Health Insurance, Science, Biotechnology, Health, Infection, Insurance, Inc., Partnership, PAS, Magnesium, Rifabutin, Stomach, Stomach cancer, Patient, EHR, Physician, Gastritis, Amoxicillin, Omeprazole, Tropical ulcer, ER-X, Red, Pharmaceutical industry, Health insurance

Phil Inc. , a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with RedHill Biopharma (Nasdaq: RDHL) (‘RedHill’) to make its medication Talicia® (omeprazole magnesium, amoxicillin, and rifabutin) available via the PhilRx Patient Access Platform.

Key Points: 
  • Phil Inc. , a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with RedHill Biopharma (Nasdaq: RDHL) (‘RedHill’) to make its medication Talicia® (omeprazole magnesium, amoxicillin, and rifabutin) available via the PhilRx Patient Access Platform.
  • The PhilRx Patient Access Platform provides end-to-end visibility into the entire prescription life cycle, starting the moment the physician writes a prescription.
  • The partnership between Phil and RedHill enables patients to receive Talicia® prescriptions quickly, easily, and affordably.
  • Our partnership with Phil will elevate our ability to eliminate access barriers to Talicia®,” said Ben Sloan, VP of Market Access at RedHill.

PM360 Announces Winners of The Ninth Annual ELITE 100 Awards

Retrieved on: 
화요일, 5월 16, 2023
Nexium, Data science, Marketing, GoodRx, EVP, Hospira, Associate, Cardinal Health, Patient, McCourt, HR, Disease, Eli Lilly and Company, Constipation, Attention, Snow, Diagnosis, Entrepreneurship, Growth, Digital marketing, Immunology, FAAN, Engagement, Organon, Caregiver, PR, Ironwood Pharmaceuticals, Exception, COVID-19, IBS-C, Health, ELITE, Boehringer Ingelheim, Abdominal pain, Sustainability, ImmunoGen, RN, Bloating, CO, Providers, Glaucoma, Lead, Mirati Therapeutics, Regulatory science, AstraZeneca, HCP, Gastroesophageal reflux disease, Veeva Systems, Novartis, Omeprazole, Management, Pharmaceutical industry, Beauty salon, Generic drug, Esomeprazole, GERD

NEW YORK, May 16, 2023 /PRNewswire/ -- PM360, the premier information resource for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device sectors, today announced the winners of its 9th Annual ELITE 100. The ELITE (Exceptional • Leaders • Innovators • Transformers • Entrepreneurs) represent the most influential people and teams in the healthcare and life sciences industries based on their career accomplishments. Out of more than 500 submissions, 100 winners are selected by the PM360 editorial staff across various categories that span every facet of the industry.

Key Points: 
  • NEW YORK, May 16, 2023 /PRNewswire/ -- PM360, the premier information resource for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device sectors, today announced the winners of its 9th Annual ELITE 100.
  • Out of more than 500 submissions, 100 winners are selected by the PM360 editorial staff across various categories that span every facet of the industry.
  • PM360 also selects one person as the "Uber ELITE," or the individual among the nominees who best personifies the criteria of a PM360 ELITE.
  • McCourt will serve as the keynote speaker at the annual ELITE 100 Awards Event to celebrate this year's winners.